Buprenorphine & Controlled Substance Treatment Agreement

Similar documents
PATIENT INTAKE: MEDICAL HISTORY. Name. Address. Phone (W) (H) (C) DOB Age SS# Emergency Contact. Relationship to patient Phone

PATIENT INTAKE: MEDICAL AND SOCIAL HISTORY (To be completed by patient)

Patient Agreement for the use of Opioid Medications

NIDA Quick Screen V1.0F1

NIDA-Modified ASSIST Prescreen V1.0 1

If you do not have health insurance, the initial appointment will be $232. Follow-up appointments will be $104.

Talking with your doctor

NIDA-Modified ASSIST - Prescreen V1.0*

ADDICTION SERVICES New Patient Paperwork To be completed by Patient PLEASE PRINT and take your time to fill out completely

PSYCHIATRIC INTAKE AND TREATMENT PLAN-PART I TO BE FILLED BY PATIENT PLEASE PRINT

Top of the World Ranch Treatment Centre Admissions Information Record Demographics

Top of the World Ranch Treatment Centre Admissions Information Record Demographics

Updated: 08/2017 DMMA Approved: 11/2017

PATIENT HISTORY DATA FORM Psychiatric, Health and Wellness, LLC 810 Michael Drive, Suite L Chesterton, IN NAME

MEDICATION MANAGEMENT AGREEMENT Pain Management Program Participation Agreement and Consent

9/9/2016. Drug Name (select from list of drugs shown) Bunavail Buccal Film (buprenorphinenaloxone) Suboxone Sublingual Film (buprenorphine-naloxone)

Child Welfare and MOMS: Building Partnerships to Improve Care

SUBOXONE (buprenorphine and naloxone) sublingual film (CIII) IMPORTANT SAFETY INFORMATION

Wasted AN INTRODUCTION TO SUBSTANCE ABUSE

Name: Gender: male female Age: Date of birth: / / Preferred phone: cell home work other. Alternate phone: cell home work other.

Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates

Prescription Opioids

Child and Youth Background Information

Role of PMPs in Preventing Substance Abuse National Conference of State Legislatures December 6, 2006 San Antonio, Tx

COMPASS RECOVERY OPIOID REHABILITATION PROGRAM QUESTIONAIRE FOR PROSPECTIVE OPIOID REHABILITATION. Name Birthdate / /

For female patients only: To the best of my knowledgei am NOT pregnant. Patients Initials:

Understanding Medication in Addiction Treatment for Drug Court Participants

Interdisciplinary Management of Opioid Use Disorder in Rural Primary Care Settings

MAT IN PREGNANCY KAYLA LIFE STAGE 1: ADOLESCENCE LIFE STAGE 2: EARLY ADULTHOOD. family History of addiction. addiction to oral opioids

SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets. Risk Evaluation and Mitigation Strategy (REMS) Program

Medication Assisted Treatment

FY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine

MEDICATION GUIDE SUBOXONE (Sub OX own) (buprenorphine and naloxone) Sublingual Tablets (CIII)

Substance-Exposed Newborn

Safe Babies Foster Parent Training Program

MEDICATION MANAGEMENT AGREEMENT

Neonatal Abstinence Syndrome Questions & Answers Webinar #1 (February 9, 2012) Webinar #2 (March 30, 3012)

problems/medications: Current supplements/vitamins/herbs: Past medical problems/medications: Other doctors/clinics seen regularly:

What Is Heroin? Examples of Opioids. What Science Says about Opioid Use Disorder and Its Treatment 6/27/2016

Medication Assisted Treatment. MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment

Taking Opioids Responsibly for Your Safety and the Safety of Others: Patient Information Guide on Long-term Opioid Therapy for Chronic Pain

Baseline Questions for Personal Feedback Report

Opioid Treatment in North Carolina SEPTEMBER 13, 2016

MN Couple Therapy Center 1611 County Road B, Suite 204 Roseville, MN

2. Is this request for a preferred medication? Y N

Medication Agreements Promoting awareness, dialogue and level-set expectations

AN INTRODUCTION TO THE TREATMENT OF OPIOID USE DISORDERS IN PRIMARY CARE

the facts about BUPRENORPHINE for Treatment of Opioid Addiction

Kiewit Building Group 12/31/2013 Volume 2 Week 1

Addiction is overwhelming. Recovery doesn t have to be.

3. Has the patient had a sustained improvement in Pain or Function (e.g. PEG scale with a 30 percent response from baseline)?

STARTING SUBOXONE IN PRIMARY CARE

ROLE OF HEALTH CARE PROVIDERS IN THE MANAGEMENT OF ALCOHOL AND DRUG USE RELATED PROBLEMS

(Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines)

Referral to the Women s Alcohol and Drug Service (WADS) Procedure

Rationale & Strategy For Integrating Buprenorphine Treatment Into Community Health Centers

Medication-Assisted Treatment. What Is It and Why Do We Use It?

Patient Information Leaflet

PATIENT TREATMENT CONTRACT

NURSING FOLLOW-UP: BUPRENORPHINE/NALOXONE BUPRENORPHINE/NALOXONE CLINIC VISITS

Annual Reports Questionnaire (ARQ) Part III: Extent, patterns and trends in drug use

NIAGARA HEALTH SYSTEM PORT COLBORNE GENERAL SITE

NURSING INTAKE. Provider Name: Provider Signature: Nursing Summary. Are you pregnant at this time?

Last Name First Middle Date of Birth Age. Residence Address City State Zip Code

Brief History of Methadone Maintenance Treatment

PATIENT IDENTIFICATION: Name: First Appointment Date: Birth Date: Address: City State Zip Home Phone #: Work #: Cell #: REFERRAL SOURCE: Referred By:

NORTHWEST AIDS EDUCATION AND TRAINING CENTER. Opioid Use Disorders. Joseph Merrill M.D., M.P.H. University of Washington April 10, 2014

The Caring Center of Wichita LLC. General Information Client Name:

Understanding Prenatal Drug Exposure

Health TALK. Toothache? Did you know?

Wilson C, Fagan E. Providing office-based treatment of opioid use disorder. Ann Fam Med. 2017;15(5):481.

SUBOXONE FILM NEW PATIENT INTRODUCTION

Close to Home A Recovery Brief WNC Recovery Recovery Ministries of the Episcopal Church

Methadone Maintenance 101

PATIENT SIGNATURE: DOB: Date:

Share the important information in this Medication Guide with members of your household.

Juniata College Health & Wellness Counseling Center INITIAL ASSESSMENT

CMBHS Clinical Management of Behavioral Health Services

About Face 615 Volunteer Parkway Bristol, TN (423)

People In Need Adult Intake Information Form (18 years old and up)

Prepublication Requirements

TELEPHONE SCREENING DEMOGRAPHIC INFO

Clinical Guidelines for the Pharmacologic Treatment of Opioid Use Disorder

WHAT YOU NEED TO KNOW ABOUT MIXING DRUGS

When you drink, your baby drinks too. Drinking alcohol during

INFORMED CONSENT FOR OPIOID TREATMENT FOR NON-CANCER/CANCER PAIN Texas Pain and Regenerative Medicine

Buprenorphine: An Introduction. Sharon Stancliff, MD Harm Reduction Coalition September 2008

[ ASSESSING THE BURDEN OF ILLICIT DRUGS AND ALCOHOL ABUSE:] Macomb County Office of Substance Abuse. A Focus on Heroin and Prescription Drug Abuse

Structured Clinical Interview on Money Mismanagement (SCIMM)

Transitional House Application

Referral to the Women s Alcohol and Drug Service (WADS) Procedure

If so, when: Demographic Information Male Transgender Height: Weight: Massachusetts Resident? Primary Language: Are you currently homeless?

MEDICATION GUIDE SUBOXONE (Sub OX own) (buprenorphine and naloxone) Sublingual Film for sublingual or buccal administration (CIII)

Triage, Assessment and Treatment Planning

Appendix F Federation of State Medical Boards

Anyone Can Become Addicted. Anyone.

Tuscarawas County Health Department. Vivitrol Treatment Consent

Methadone/ Suboxone Treatment in federal prison

Opiate Use Disorder and Opiate Overdose

Addiction History. Patient Assessment. Objectives. Cost. Initial Screen. Patient Assessment 25/04/2017. Substances. Age Started

Transcription:

Buprenorphine & Controlled Substance Treatment Agreement I agree to accept the following treatment contract for buprenorphine office-based opioid addiction treatment: 1. I will keep my medication in a safe and secure place away from children (e.g., in a lock box). My plan is to store it (describe where and in what)? 2. I will take the medication exactly as my doctor prescribes. If I want to change my medication dose, I will speak with the doctor first. Taking more than my doctor prescribes or taking it more than once daily as my doctor prescribes is medication misuse and may result in supervised dosing at the clinic. Taking the medication by snorting or by injection is also medication misuse and may result in supervised dosing at the clinic, referral to a higher level of care, or change in medication based on the doctor s evaluation. 3. I will be on time to my appointments and be respectful to the office staff and other patients. 4. I will keep my doctor informed of all my medications (including herbs and vitamins) and medical problems. 5. I agree not to obtain or take prescription opioid medications prescribed by any other doctor. 6. If I am going to have a medical procedure that will cause pain, I will let my doctor know in advance so that my pain will be adequately treated. 7. If I miss an appointment or lose my medication, I understand that I will not get more medication until my next office visit. I may also have to start having supervised buprenorphine dosing. 8. If I come to the office intoxicated, I understand that the doctor will not see me, and I will not receive more medication until the next office visit. I may also have to start having supervised buprenorphine dosing. 9. I understand that it is illegal to give away or sell my medication this is diversion. If I do this, my treatment will no longer include unsupervised buprenorphine dosing and may require referral to a high level of care, supervised dosing at our clinic, and/or a change in medication based on the doctor s evaluation. 10. Violence, threatening language or behavior, or participation in any illegal activity at the office will result in treatment termination from our clinic. 11. I understand that random urine drug testing is a treatment requirement. If I do not provide a urine sample, it will count as a positive drug test. 1

12. I understand that I will be called at random times to bring my medication bottle into the office for a pill count. Missing medication doses could result in requirement for supervised dosing or referral to a higher level of care at this clinic or potentially at another treatment provider based on your individual needs. 13. I understand that initially I will have weekly office visits until I am stable. I will get a prescription for 7 days of medication at each visit. 14. I can be seen every two weeks in the office starting the second month of treatment if I have two negative urine drug tests in a row. I will then get a prescription for 14 days of medication at each visit. 15. I will go back to weekly visits if I have a positive drug test. I can go back to visits every two weeks when I have two negative drug tests in a row again. 16. I may be seen less than every two weeks based on goals made by me and my doctor. 17. I understand that people have died by mixing buprenorphine with other drugs like alcohol and benzodiazepines (drugs like Valium, Klonopin and Xanax ). 18. I understand that treatment of opioid addiction involves more than just taking my medication. I agree to comply with my doctor s recommendations for additional counseling and/or for help with other problems. 19. I understand that there is no fixed time for being on buprenorphine and that the goal of treatment is to stop using all illicit drugs and become successful in all aspects of my life. 20. I understand that I may experience opioid withdrawal symptoms when I go off buprenorphine. 21. I have been educated about the other two FDA-approved medications for opioid dependence treatment, methadone and naltrexone. 22. If female, I have been educated about the increased chance of pregnancy when stopping illicit opioid use and starting buprenorphine treatment and offered methods for preventing pregnancy. 23. If female, I have been educated about the effects of poor diet, illicit opioid use, use of dirty needles/sharing injection equipment, physical and mental trauma, and lack of pre-natal medical, substance use and mental health care during pregnancy and how these things can adversely affect my health and my current or future fetus/newborn s health. I understand that neonatal abstinence syndrome can occur when taking illicit opioids and that neonatal abstinence syndrome (NAS) is less severe, but can still occur, when pregnant women take methadone or buprenorphine as prescribed/dispensed in substance use disorder treatment. Cigarette smoking can make the severity of NAS worse and cause pre-term birth and small babies. Alcohol use can cause significant cognitive/brain damage in fetuses and newborns. PRINT NAME SIGNATURE DATE Transcultural Care 2

Authorization to Leave Personal Health Information by Alternative Means this includes information pertaining to Drug, Alcohol & Psychiatric Conditions Patient Name: DOB: Patient Mailing Address: Please fill all that apply: May leave/share message on voicemail at home # ( ) May leave/share message with spouse (name) May leave/share info with other family (name) May call or text detailed message on cell phone # ( ) May leave/share detailed message at a different # ( ) May send message to this email address 3

Substance Use History No Yes/Past/Now Route How Much How Often Quantity Date/Time Last Use Alcohol Caffeine Crystal Meth Ecstasy Heroin Inhalants LSD or Hallucinogens Marijuana Methadone Pain Killers PCP Stimulants (pills) Sleeping pills Tranquilizers Other 4

FOLLOW UP VISIT FOR SUBOXONE Name: DOB: Date: SYMPTOMS (please circle one) Stable: Worse: Improved: Unchanged: Have you had any cravings? (please circle) Since your last visit, have you relapsed? (if yes please specify which substance and when) Have you attended AA/NA meetings since your last visit? (if yes dates and location) Have you established a support network? (family, non-drug using friends, spouse, significant other) 5